IL19 and multiple sclerosis: However, there was a significant reduction in IL-19 expression with IFNβ treatment in PBMCs of multiple sclerosis patients24 (log-fold of 1.3 ± 0.4; P = 0.004) (Supplementary Fig. 2D).